Tumor Suppressor Par-4
Springer International Publishing (Verlag)
978-3-030-73571-5 (ISBN)
lt;b> Vivek M. Rangnekar, Ph.D. is Professor and Alfred Cohen Chair in Oncology Research in the Department of Radiation Medicine and Associate Director of the Markey Cancer Center at the University of Kentucky. His laboratory studies the molecular cross-talk between oncogenes and tumor suppressor genes in an effort to tilt the balance in favor of tumor suppressor function. Dr. Rangnekar originally discovered and identified the tumor suppressor protein Par-4/PAWR in 1993.
Discovery and Overview of Par-4.- Par-4 in cell cycle regulation.- Conformational studies of the Par-4 C-terminal Domain.- Structural analysis of Par-4 and crystallographic analysis of the regulatory domain.- Regulation of Par-4 by Ubiquitinases.- REGULATION OF PAR-4 FUNCTION BY PHOSPHORYLATION.- Role of Par-4 in GRP78 translocation.- PAR-4 in the regulation of stem cell death and embryo development.- RASSF2 and the PAR-4 connection.- Regulation of tumor suppressor Par-4 by ceramide.- PAWR as a direct SRC-1/HOXC11 suppression target.- Index.
Erscheinungsdatum | 10.01.2022 |
---|---|
Zusatzinfo | X, 323 p. 84 illus., 81 illus. in color. |
Verlagsort | Cham |
Sprache | englisch |
Maße | 155 x 235 mm |
Gewicht | 661 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
Medizin / Pharmazie ► Studium | |
Schlagworte | Amida • Apoptosis • Cancer cells • cell surface receptor GRP78 • clinical trial • DAPK • FDA-approved drugs • par-4 • PKA • Prostate • Protein • Stem Cells • THAP1 • Translational research • Zebrafish |
ISBN-10 | 3-030-73571-0 / 3030735710 |
ISBN-13 | 978-3-030-73571-5 / 9783030735715 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich